Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

/p>

3 months to September 9 months to September 30, 30, 2011 2010 2011 2010 $M $M $M $M Net cash provided by operating activities 178.7 142.0 664.2 612.0 Capital expenditure (1) (40.9) (53.5) (135.9) (139.7) Non GAAP free cash flow 137.8 88.5 528.3 472.3

(1) Capital expenditure for the nine months ended September 30, 2010 excludes capital expenditure relating to the acquisition of Lexington Technology Park.

Non GAAP net debt comprises:

September 30, December 31, 2011 2010 $M $M Cash and cash equivalents 276.4 550.6 Restricted cash 21.0 26.8 Convertible bonds (1,100.0) (1,100.0) Building finance obligation (8.3) (8.4) Non GAAP net debt (810.9) (531.0)

NOTES TO EDITORS

THE "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicines products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
(Date:7/27/2015)... 2015 According to the new Market ... Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by ... , Asia-Pacific , Rest of the ... media market was valued at $247.7 million in 2014, which ... at a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/27/2015)... 2015 Junto Health, a company that helps ... develop new technology solutions, today announced the launch of ... leader in health care policy consulting. Working together with ... collaborative innovation process while, at the same time, they ... policy, health care finance and the delivery of health ...
Breaking Biology Technology:Brady Releases “3 Roads to GHS Labels” Video 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... Vicus Therapeutics, LLC, an,oncology-focused, clinical-stage, biopharmaceutical ... Clinical Research and Development, is,scheduled to present ... Tri-Conference on March 28st at 1:35 p.m. ... San Francisco. Dr. Rao will focus on,considerations ...
... to HistoRx AQUA(R) ... for tissue biomarker analysis-, NEW HAVEN, Conn., March ... a three-year agreement with Eli Lilly and Company,(NYSE: ... tissue biomarker,analysis widely available to Lilly researchers and clinicians ...
... company on track for Phase I/II trial ... ... Genetics Inc.,(TSX: SBS), a biotechnology company developing a portfolio of therapeutic,proteins ... toxicology study in animals to demonstrate the safety and,comparability of its ...
Cached Biology Technology:HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 2HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 3SemBioSys initiates toxicology study for safflower-produced insulin 2SemBioSys initiates toxicology study for safflower-produced insulin 3
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... French . Montreal, April 27, 2010 - Chagas ... world. It affects more than 10 million people, primarily in the ... year. A reliable and rapid diagnosis is the key in the ... impossible. Dr. Momar Ndao and his team at the Research Institute ...
... of microbes living underground could determine the amount of carbon ... a study published online this week in Nature Geoscience ... the Yale School of Forestry & Environmental Studies have found ... efficient over time in converting carbon in soil into carbon ...
... J. Sejnowski, Ph.D., whose work on neural networks helped ... 1980s, has been elected a member of the National ... during its 147th annual meeting in Washington, DC. Election ... original research, and is considered one of the highest ...
Cached Biology News:Major breakthrough in the diagnosis of parasitic diseases 2Microbes contribute less to climate warming 2Salk scientist Terrence Sejnowski elected to National Academy of Sciences 2
...
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
... is suitable for use with ... incubating with 0.1% diethylpyrocarbonate (DEPC) ... the DEPC.DNase/RNase-Free Distilled WaterDistilled Water ... all molecular biology applications. It ...
Biology Products: